Founded in 2021, CurifyLabs develops an automated Compounding System Solution that combines proprietary software, GMP-manufactured excipient bases and 3D printing to prepare personalised medications. Its platform includes integrated quality-control features and aims to improve consistency, precision and speed versus manual pharmacy compounding. CurifyLabs’ technology is used by pharmacies in 21 US states and across Europe. The company plans to expand its US operations and invest in its supply chain and customer support as it scales. CurifyLabs is actively developing products on its platform, including the PharmaPrinter Aurum, and recently raised €12 million in a Series A to support these efforts.

Total raised

$23M

Funding rounds

3

Latest round

Equity

Latest activity

May 2025